دورية أكاديمية
Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology.
| العنوان: | Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. |
|---|---|
| المؤلفون: | German CA; Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA., Baum SJ; Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA., Ferdinand KC; Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA., Gulati M; Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Polonsky TS; Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA., Toth PP; Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD and CGH Medical Center, Sterling, IL, USA., Shapiro MD; Section on Cardiovascular Medicine, Center for Prevention of Cardiovascular Disease, Wake Forest University School of Medicine, Winston-Salem, NC, USA. |
| المصدر: | American journal of preventive cardiology [Am J Prev Cardiol] 2022 Nov 16; Vol. 12, pp. 100432. Date of Electronic Publication: 2022 Nov 16 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101769122 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-6677 (Electronic) Linking ISSN: 26666677 NLM ISO Abbreviation: Am J Prev Cardiol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Amsterdam] : Elsevier B.V., [2020]- |
| مستخلص: | Remarkable transformations in science and healthcare have resulted in declines in mortality from cardiovascular disease over the past several decades, largely driven by progress in prevention and treatment of persons at risk. However, these trends are now beginning to stall, as our county faces increases in cardiovascular risk factors including overweight and obesity, type 2 diabetes mellitus, and metabolic syndrome. Furthermore, poor long-term adherence to a healthy lifestyle and lifesaving pharmacotherapy have exacerbated these trends, with recent data suggesting unprecedented increases in cardiovascular morbidity and mortality. A paradigm shift is needed to improve the cardiovascular health of our nation. Preventive cardiology, a growing subspecialty of cardiovascular medicine, is the practice of primordial, primary, and secondary prevention of all cardiovascular diseases. Preventive cardiologists and preventive cardiology specialists are well equipped with the knowledge and skill-set necessary to reduce deaths related to the growing burden of heart disease and its risk factors. Despite dedicated efforts, cardiovascular disease remains the leading killer of men and women in the United States. Although there is little debate regarding the importance of prevention, many healthcare professionals question the need for preventive cardiology as a distinct subspecialty. Additionally, the field's growth has been hampered by a lack of organization and standardization, and variability of training within programs across the country. The purpose of this document is to delineate the key attributes that define the field of preventive cardiology according to the American Society for Preventive Cardiology. Competing Interests: Seth Baum: Serves on the advisory board for, provides consulting, and performs clinical research for Amgen, Sanofi/Regeneron, Esperion, Akcea, AstraZeneca, Boehringer Ingelheim/Lilly, Novo Nordisk, and Gemphire. He is a speaker for Amgen, Boehringer Ingelheim/Lilly, Novo Nordisk, and Aralez, and serves as president of Excel Medical Clinical Trials, LLC and Preventive Cardiology, Inc. Keith Ferdinand: Consultant for Amgen, Novartis, Medtronic, and Pfizer. Michael Shapiro: Serves on the advisory board for Amgen, Novartis, and Novo Nordisk. He is a consultant for Regeneron. Peter Toth: Speaker for Amarin, Amgen, Esperion, and Novo Nordisk. He is a consultant for Amarin, Merck, Novartis, and Resverlogix. The rest of the authors do not report any disclosures or competing interests. (© 2022 The Authors.) |
| References: | Heart. 2015 Dec;101(24):1954-60. (PMID: 26246401) Annu Rev Genet. 1979;13:259-89. (PMID: 231932) Int J Epidemiol. 2015 Dec;44(6):1800-13. (PMID: 26705418) Cochrane Database Syst Rev. 2019 Jan 29;1:CD003331. (PMID: 30695817) J Am Heart Assoc. 2018 Jan 15;7(2):. (PMID: 29335319) J Clin Lipidol. 2018 Sep - Oct;12(5):1113-1122. (PMID: 30055973) Circulation. 1998 May 12;97(18):1837-47. (PMID: 9603539) Am J Prev Cardiol. 2022 Apr 06;10:100342. (PMID: 35517870) JAMA. 2001 Jul 25;286(4):421-6. (PMID: 11466120) N Engl J Med. 2018 Oct 18;379(16):1509-1518. (PMID: 30221597) N Engl J Med. 2018 Feb 8;378(6):497-499. (PMID: 29341841) J Am Coll Cardiol. 2018 Feb 13;71(6):670-687. (PMID: 29420964) JAMA Intern Med. 2019 Aug 01;179(8):1105-1112. (PMID: 31141585) Eur Heart J. 2021 Sep 7;42(34):3227-3337. (PMID: 34458905) J Am Coll Cardiol. 2021 Nov 2;78(18):1831-1843. (PMID: 34711342) Circulation. 2019 Jun 18;139(25):e1082-e1143. (PMID: 30586774) N Engl J Med. 2015 Jun 18;372(25):2448-50. (PMID: 26039520) Eur Heart J. 2020 Jun 21;41(24):2313-2330. (PMID: 32052833) J Am Coll Cardiol. 2018 Apr 24;71(16):1729-1737. (PMID: 29673463) Am J Prev Cardiol. 2022 Mar 02;10:100323. (PMID: 35284849) Circulation. 2008 Feb 12;117(6):743-53. (PMID: 18212285) Clin Cardiol. 2016 Nov;39(11):627-630. (PMID: 27783842) Circulation. 2005 Jan 25;111(3):369-76. (PMID: 15668354) Heart Lung Circ. 2015 Jul;24(7):696-704. (PMID: 25697383) J Am Heart Assoc. 2018 Mar 22;7(6):. (PMID: 29567764) CMAJ. 2017 Mar 13;189(10):E391-E397. (PMID: 28385819) Am J Cardiol. 2012 Jul 1;110(1):124-8. (PMID: 22482864) Circulation. 2006 Feb 14;113(6):791-8. (PMID: 16461820) Circulation. 2020 Mar 31;141(13):e705-e736. (PMID: 32100573) J Am Heart Assoc. 2017 Dec 29;7(1):. (PMID: 29288154) Circulation. 2017 Mar 21;135(12):e726-e779. (PMID: 27840333) Am J Prev Cardiol. 2022 Mar 15;10:100335. (PMID: 35342890) J Biol Chem. 1974 Aug 25;249(16):5153-62. (PMID: 4368448) Lancet. 2015 Jun 13;385(9985):2383-91. (PMID: 25788230) J Am Coll Cardiol. 2021 Oct 19;78(16):1573-1583. (PMID: 34649694) N Engl J Med. 2019 Dec 26;381(26):2497-2505. (PMID: 31733140) Eur Heart J. 2020 Jan 7;41(2):255-323. (PMID: 31497854) J Am Coll Cardiol. 2016 Aug 23;68(8):789-801. (PMID: 27539170) Curr Atheroscler Rep. 2012 Feb;14(1):1-10. (PMID: 22102062) Circulation. 2022 Aug 2;146(5):e18-e43. (PMID: 35766027) Nat Rev Immunol. 2006 Jul;6(7):508-19. (PMID: 16778830) Circulation. 2018 May 1;137(18):e495-e522. (PMID: 29618598) Hypertension. 2018 Nov;72(5):e53-e90. (PMID: 30354828) J Am Coll Cardiol. 2007 Jan 30;49(4):403-14. (PMID: 17258085) J Am Coll Cardiol. 2021 Nov 2;78(18):1817-1830. (PMID: 34711341) PLoS One. 2020 Oct 13;15(10):e0240539. (PMID: 33048982) Can J Cardiol. 2017 Feb;33(2):219-231. (PMID: 27956043) N Engl J Med. 2008 Nov 20;359(21):2195-207. (PMID: 18997196) Atherosclerosis. 2021 Jan;316:71-72. (PMID: 33256996) Circulation. 2015 Dec 22;132(25):2424-47. (PMID: 26644329) N Engl J Med. 2018 Oct 18;379(16):1529-1539. (PMID: 30146931) Circulation. 2017 Feb 7;135(6):495-498. (PMID: 28153984) J Clin Endocrinol Metab. 2016 Sep;101(9):3306-15. (PMID: 27300572) J Am Heart Assoc. 2019 Dec 17;8(24):e013225. (PMID: 31838973) J Am Coll Cardiol. 2022 Oct 4;80(14):1287-1298. (PMID: 36175048) Am J Prev Cardiol. 2020 Jun 06;2:100028. (PMID: 34327455) Lancet. 2022 May 14;399(10338):1876-1885. (PMID: 35525255) J Am Coll Cardiol. 2021 Dec 14;78(24):2460-2470. (PMID: 34886968) JAMA. 2012 Nov 7;308(17):1795-801. (PMID: 23117780) Prev Med. 2004 Oct;39(4):815-22. (PMID: 15351551) JACC Case Rep. 2022 Jul 20;4(14):911-914. (PMID: 35912322) N Engl J Med. 2015 Jun 18;372(25):2387-97. (PMID: 26039521) Heart. 2018 Sep;104(17):1403-1410. (PMID: 29654096) N Engl J Med. 1998 Jun 4;338(23):1650-6. (PMID: 9614255) J Am Heart Assoc. 2021 Apr 6;10(7):e019681. (PMID: 33761755) Circulation. 2019 Sep 10;140(11):e563-e595. (PMID: 30879339) J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. (PMID: 32771263) J Am Coll Cardiol. 2008 Jul 1;52(1):17-23. (PMID: 18582630) Circulation. 2011 Aug 23;124(8):967-90. (PMID: 21788592) N Engl J Med. 2020 Nov 5;383(19):1838-1847. (PMID: 32865380) Heart. 2018 Jul;104(13):1069-1075. (PMID: 29335253) N Engl J Med. 2018 Jun 21;378(25):e34. (PMID: 29897866) Circulation. 2010 Feb 2;121(4):586-613. (PMID: 20089546) Am J Public Health Nations Health. 1959 Oct;49:1349-56. (PMID: 13814552) Prev Med. 2018 Sep;114:140-148. (PMID: 29953898) Atherosclerosis. 2012 Jan;220(1):128-33. (PMID: 21764060) J Am Heart Assoc. 2019 Jun 18;8(12):e012406. (PMID: 31165670) J Am Heart Assoc. 2019 May 21;8(10):e012873. (PMID: 31092095) N Engl J Med. 2012 Jan 5;366(1):9-19. (PMID: 22077192) Hypertension. 2018 Jun;71(6):e13-e115. (PMID: 29133356) Circulation. 2021 May 11;143(19):1831-1834. (PMID: 33820441) Hypertension. 2016 Jun;67(6):1085-92. (PMID: 27091893) Circulation. 2010 Mar 30;121(12):1455-8. (PMID: 20351303) Heart. 2012 Dec;98(24):1763-77. (PMID: 23077152) Circulation. 2020 Mar 3;141(9):e139-e596. (PMID: 31992061) JAMA. 2012 Jan 4;307(1):56-65. (PMID: 22215166) Circulation. 2020 May 12;141(19):1541-1553. (PMID: 32233663) Circulation. 1979 Jan;59(1):8-13. (PMID: 758126) JAMA. 2020 Mar 24;323(12):1151-1160. (PMID: 32207799) Circulation. 2021 Mar 16;143(11):1157-1172. (PMID: 33720773) J Am Coll Cardiol. 2019 Jul 2;73(25):3259-3266. (PMID: 31248546) Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e005263. (PMID: 30571339) Circulation. 2004 Jan 27;109(3):433-8. (PMID: 14744958) J Am Coll Cardiol. 2018 Jun 12;71(23):2691-2701. (PMID: 29880130) Circ Cardiovasc Qual Outcomes. 2014 May;7(3):453-60. (PMID: 24803472) Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005562. (PMID: 31416347) Sports Med. 2017 Sep;47(9):1769-1793. (PMID: 28393328) Am J Hypertens. 2022 Mar 8;35(3):214-216. (PMID: 35259235) J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959. (PMID: 24239921) Circulation. 1967 Apr;35(4):734-44. (PMID: 6024013) Mayo Clin Proc. 2017 Feb;92(2):234-242. (PMID: 27855953) Circulation. 2011 Jan 25;123(3):327-34. (PMID: 21263005) Eur J Prev Cardiol. 2016 Jan;23(2):178-86. (PMID: 25331207) J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. (PMID: 29146535) N Engl J Med. 2021 Oct 14;385(16):1451-1461. (PMID: 34449189) Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. (PMID: 34964831) Eur Heart J. 2012 Dec;33(23):2955-62. (PMID: 22843447) Can Med Assoc J. 1967 Mar 25;96(12):811-2. (PMID: 6020881) Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):174-9. (PMID: 19247184) J Clin Lipidol. 2017 Jul - Aug;11(4):929-937. (PMID: 28647412) Circ Cardiovasc Qual Outcomes. 2018 Mar;11(3):e004249. (PMID: 29545393) Lancet. 2018 Jan 20;391(10117):205-218. (PMID: 29132879) Cochrane Database Syst Rev. 2021 Nov 6;11:CD001800. (PMID: 34741536) J Am Coll Cardiol. 2019 Dec 3;74(22):2743-2754. (PMID: 31727424) Circulation. 2022 Feb 22;145(8):e153-e639. (PMID: 35078371) Endocr Pract. 2016 Jul;22(7):842-84. (PMID: 27472012) JAMA. 2019 Nov 26;322(20):1996-2016. (PMID: 31769830) JAMA Cardiol. 2019 Feb 1;4(2):182-183. (PMID: 30698616) Diabetes Care. 2013 Aug;36 Suppl 2:S233-9. (PMID: 23882051) Circ Cardiovasc Imaging. 2021 Apr;14(4):e011701. (PMID: 33827231) Am J Prev Cardiol. 2022 Jan 20;9:100318. (PMID: 35146468) BMJ. 2012 Mar 26;344:e1389. (PMID: 22451477) JAMA. 2020 Dec 8;324(22):2268-2280. (PMID: 33190147) J Womens Health (Larchmt). 2018 Nov;27(11):1385-1388. (PMID: 30199308) Diabetologia. 2019 Jun;62(6):905-914. (PMID: 30843102) Fertil Steril. 2019 Jan;111(1):138-146. (PMID: 30458992) N Engl J Med. 2019 Jan 3;380(1):11-22. (PMID: 30415628) Circulation. 2019 Sep 10;140(11):e596-e646. (PMID: 30879355) Lancet. 2018 Sep 22;392(10152):1036-1046. (PMID: 30158069) Diabet Med. 2006 May;23(5):469-80. (PMID: 16681555) Circulation. 2021 Jul 20;144(3):e56-e67. (PMID: 34148375) J Clin Med. 2022 Apr 14;11(8):. (PMID: 35456292) Lancet. 2018 Jan 20;391(10117):219-229. (PMID: 29132880) Am J Prev Cardiol. 2020 Nov 19;4:100106. (PMID: 34327475) J Am Med Assoc. 1953 Jul 18;152(12):1090-3. (PMID: 13052433) J Am Coll Cardiol. 2019 Jan 29;73(3):291-301. (PMID: 30678759) N Engl J Med. 2017 Oct 5;377(14):1319-1330. (PMID: 28844192) Circulation. 2021 Feb 23;143(8):e254-e743. (PMID: 33501848) J Am Coll Cardiol. 2015 May 5;65(17):1754-62. (PMID: 25777651) J Am Coll Cardiol. 2015 Sep 1;66(9):1050-67. (PMID: 26314534) J Am Heart Assoc. 2017 Mar 17;6(3):. (PMID: 28314800) J Am Coll Cardiol. 2021 Mar 30;77(12):1564-1575. (PMID: 33766264) J Am Coll Cardiol. 2021 Mar 30;77(12):1576-1589. (PMID: 33766265) Lancet Public Health. 2022 Mar;7(3):e219-e228. (PMID: 35247352) Am J Epidemiol. 2020 Sep 1;189(9):951-962. (PMID: 32242233) JACC Cardiovasc Imaging. 2021 May;14(5):990-1002. (PMID: 33129734) Ann Intern Med. 2017 Oct 03;167(7):456-464. (PMID: 28847012) Circulation. 2017 Jun 13;135(24):2320-2332. (PMID: 28389572) J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175) J Am Coll Cardiol. 2020 Apr 7;75(13):1582-1592. (PMID: 32241375) Ann Intern Med. 1961 Jul;55:33-50. (PMID: 13751193) JAMA Cardiol. 2021 Feb 1;6(2):179-187. (PMID: 33112372) Eur Heart J. 2020 Apr 14;41(15):1479-1486. (PMID: 31951255) JAMA. 2019 Jan 22;321(3):277-287. (PMID: 30667501) JAMA. 2020 Sep 22;324(12):1190-1200. (PMID: 32902588) Heart. 2009 Feb;95(2):125-9. (PMID: 18381374) J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. (PMID: 30894319) Circulation. 2021 Dec 7;144(23):e472-e487. (PMID: 34724806) JAMA. 1971 May 17;216(7):1185-7. (PMID: 5108403) |
| فهرسة مساهمة: | Keywords: ACC, american college of cardiology; AHA, american heart association; ASPC, american society for preventive cardiology; Atherosclerosis; BMI, body mass index; CAC, coronary artery calcium; CCTA, coronary CT angiography; CMS, centers for medicare and medicaid services; CR, cardiac rehabilitation; CVD, cardiovascular disease; CVH, cardiovascular health; Cardiovascular disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FHS, framingham heart study; GLP1-RA, glucagon-like peptide 1 receptor agonists; LDL-C, low-density lipoprotein cholesterol; Mets, metabolic syndrome; NHANES, national health and nutrition examination survey; NIH, national institutes of health; NNT, number needed to treat; OSA, obstructive sleep apnea; PA, physical activity; PAD, peripheral artery disease; PCE, pooled cohort equations; PCSK9, proprotein convertase subtilisin kexin 9; Preventive cardiology; Primary prevention; Primordial prevention; Risk assessment; SES, socioeconomic status; SGLT2i, sodium glucose cotransporter 2 inhibitors; Secondary prevention; T2DM, type 2 diabetes mellitus; US, united states |
| تواريخ الأحداث: | Date Created: 20221125 Latest Revision: 20221126 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9679464 |
| DOI: | 10.1016/j.ajpc.2022.100432 |
| PMID: | 36425534 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2666-6677 |
|---|---|
| DOI: | 10.1016/j.ajpc.2022.100432 |